CEPHALOTAXINE 4-METHYL (2R)-2-HYDROXY-2-(4-HYDROXY-4-METHYLPENTYL)BUTANEDIOATE (ESTER)
Childhood Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, ChinaSmall moleculePhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
64 Active assets in the Childhood Acute Lymphoblastic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VINCRISTINE SULFATE National Cancer Institute (NCI) | Phase 3 | BBB |
CYTARABINE Children's Oncology Group | Phase 3 | BBB |
METHOTREXATE Children's Oncology Group | Phase 3 | BBB |
Cyclophosphamide St. Jude Children's Research Hospital | Phase 3 | BBB |
FILGRASTIM St. Jude Children's Research Hospital | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
CEPHALOTAXINE 4-METHYL (2R)-2-HYDROXY-2-(4-HYDROXY-4-METHYLPENTYL)BUTANEDIOATE (ESTER) is also rated in:
acute myeloid leukemia, FLT3 internal tandem duplicationDormant
B
Indicative · Phase 2
57 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →